Louis Gendron

Prix et distinctions

• (2019) Nominé/Nominee - Prix Pharmacologie. Université de Sherbrooke. (Prix).
• (2017) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honneur).
• (2016) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honneur).
• (2016) Nominé/Nominee - Prix Pharmacologie. Université de Sherbrooke. (Prix).
• (2015) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honneur).
• (2015) Nominé/Nominee - Prix Pierre-et-Danielle-Bourgaux. Université de Sherbrooke. (Prix).
• (2015) Prix du Doyen. Université de Sherbrooke. (Prix).
• (2014) Mention d'honneur du Doyen, performance professorale exceptionnelle. Université de Sherbrooke. (Honneur).
• INRC Young Investigator Award. International Narcotics Research Conference. (Prix).
• Nominé/Nominee - Prix Diego-Bellabarba (mentorat). Université de Sherbrooke. (Prix).
• Récipiendaire/Recipient Prix Diego-Bellabarba (mentorat/mentoring). Université de Sherbrooke. (Prix).

Financement

• Subvention. (Obtenu). Cochercheur. A prospective translational model of the therapeutic potential of cannabidiol in reducing acute pain symptoms and opioid usage following traumatic injury.. Instituts de Recherche en Santé du Canada (IRSC). Team Grant: Cannabis Research in Priority Areas. 1 499 925 $. (2020-2025)
• Subvention. (Obtenu). Chercheur principal. Role, function, and regulation of the delta opioid receptor and its implications for the treatment of pain (ranked 3rd). Instituts de Recherche en Santé du Canada (IRSC). Project Grant Competition. 967 725 $. (2019-2024)
• Subvention. (Obtenu). Chercheur principal. Neurobiology and molecular mechanisms of the opioid system. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Discovery Grant. 145 000 $. (2018-2023)
• Subvention. (Obtenu). Cocandidat. Novel Supramolecular Drugs for a “Supramolecular” Disease. Fonds de recherche du Québec - Nature et technologies (FRQNT). Fonds de la Recherche Scientifique - FNRS. Programme bilatéral de recherche collaborative Québec-Fédération Wallonie-Bruxelles. 300 000 $. (2019-2022)
• Subvention. (Obtenu). Cocandidat. Chronic Pain Network (Strategy for Patient–Oriented Research (SPOR) Networks in Chronic Disease). Canadian Institutes of Health Research (CIHR) and partnerships. Strategy for Patient–Oriented Research (SPOR) Networks in Chronic Disease. 25 000 000 $. (2016-2022)
• Subvention. (Obtenu). Cocandidat. Structural mechanisms of prostaglandins facilitated transport. Institut de pharmacologie de Sherbrooke. Pilot project grants. 40 000 $. (2019-2021)
• Subvention. (Terminé). Cochercheur. Médicaments supramoléculaires pour maladies supramoléculaires. Institut de pharmacologie de Sherbrooke (IPS). concours IPS-Innovation. 30 000 $. (2018-2020)
• Subvention. (Terminé). Candidat principal. Planning and Dissemination Grant - 20th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec (ranked 1st). Instituts de Recherche en Santé du Canada (IRSC). Planning and Dissemination Grant. 20 000 $. (2019-2020)
• Subvention. (Terminé). Cocandidat. Planning and Dissemination Grant - Dissiper la fumée : Cannabis et Santé Colloque scientifique conjoint du Réseau québécois de recherche sur les médicaments, du Réseau santé respiratoire et du Réseau québécois de recherche sur la douleur. Instituts de Recherche en Santé du Canada (IRSC). Planning and Dissemination Grant. 20 000 $. (2019-2020)
• Subvention. (Terminé). Cocandidat. The potential of Cannabidiol as a therapeutic agent for concussion. Instituts de Recherche en Santé du Canada (IRSC). Catalyst Grant - Cannabis Research in Urgent Priority Areas. 125 000 $. (2019-2020)
• Subvention. (Terminé). Chercheur principal. Design, synthesis and characterization of novel enkephalin analogs for the delta opioid receptor. (2014-2019)
• Bourse de recherche. (Terminé). Candidat principal. Rôles, régulation et mécanismes d'action des récepteurs opioïdergiques dans le contrôle de la douleur (Rang: 2/13). (2015-2019)
• Subvention. (Terminé). Chercheur principal. Delta opioid receptor as a target for migraine-induced allodynia. RQRD-FRQS. Pilot-project grants. 25 000 $. (2017-2019)
• Subvention. (Terminé). Chercheur principal. Rôle, régulation, mécanismes d'action du récepteur opioïde delta dans le contrôle de la douleur. (2012-2018)

Publications

Articles de revue

• Degrandmaison J , Grisé O , Parent JL , Gendron L. (2022). Differential barcoding of opioid receptors trafficking. Journal of neuroscience research 100 (1), 99-128. (Article publié).
• Degrandmaison J , Rochon-Haché S , Parent JL , Gendron L. (2022). Knock-In Mouse Models to Investigate the Functions of Opioid Receptors in vivo. Frontiers in cellular neuroscience 16 807549. (Article publié).
• Sean M , Coulombe-Lévêque A , Bordeleau M , Vincenot M , Gendron L , Marchand S , Léonard G. (2021). Comparison of Thermal and Electrical Modalities in the Assessment of Temporal Summation of Pain and Conditioned Pain Modulation. Frontiers in pain research (Lausanne, Switzerland) 2 659563. (Article publié).
• Vincenot M , Coulombe-Lévêque A , Sean M , Camirand Lemyre F , Gendron L , Marchand S , Léonard G. (2021). Development and Validation of a Predictive Model of Pain Modulation Profile to Guide Chronic Pain Treatment: A Study Protocol. Frontiers in pain research (Lausanne, Switzerland) 2 606422. (Article publié).
• Fréchette L , Degrandmaison J , Binda C , Boisvert M , Côté L , Michaud T , Lalumière MP , Gendron L , Parent JL. (2021). Identification of the interactome of the DP1 receptor for Prostaglandin D2: Regulation of DP1 receptor signaling and trafficking by IQGAP1. Biochimica et biophysica acta. General subjects 1865 (11), 129969. (Article publié).
• Sean M , Coulombe-Lévêque A , Vincenot M , Martel M , Gendron L , Marchand S , Léonard G. (2021). Transcutaneous electrical nerve stimulation (TENS): towards the development of a clinic-friendly method for the evaluation of excitatory and inhibitory pain mechanisms. Canadian journal of pain = Revue canadienne de la douleur 5 (1), 56-65. (Article publié).
• Berthiaume S , Abdallah K , Blais V , Gendron L. (2020). Alleviating pain with delta opioid receptor agonists: evidence from experimental models. Journal of neural transmission (Vienna, Austria : 1996) 127 (4), 661-672. (Article publié).
• *Jade Degrandmaison, *Khaled Abdallah, *Véronique Blais, Samuel Génier, Marie-Pier Lalumière, *Francis Bergeron, Catherine M. Cahill, Jim Boulter, Christine L. Lavoie, Jean-Luc Parent, Louis Gendron. (2020). In vivo mapping of a GPCR interactome using knock-in mice. Proc. Natl. Acad. Sci. USA 117 (23), 13105-13116. (Article publié).
• Gonzalez S , Dumitrascuta M , Eiselt E , Louis S , Kunze L , Blasiol A , Vivancos M , Previti S , Dewolf E , Martin C , Tourwè D , Cavelier F , Gendron L , Sarret P , Spetea M , Ballet S. (2020). Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. Journal of medicinal chemistry 63 (21), 12929-12941. (Article publié).
• Béatrice Quirion, Francis Bergeron, Véronique Blais, Louis Gendron. (2020). The Delta-Opioid Receptor; a Target for the Treatment of Pain. Front. Mol. Neurosci. 13 52. (Article publié).
• Avet C , Sturino C , Grastilleur S , Gouill CL , Semache M , Gross F , Gendron L , Bennani Y , Mancini JA , Sayegh CE , Bouvier M. (2020). The PAR2 inhibitor I-287 selectively targets Gα q and Gα 12/13 signaling and has anti-inflammatory effects. Communications biology 3 (1), 719. (Article publié).
• Eiselt É , Otis V , Belleville K , Yang G , Larocque A , Régina A , Demeule M , Sarret P , Gendron L. (2020). Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain. The Journal of pharmacology and experimental therapeutics 374 (1), 52-61. (Article publié).
• Claff, T., Yu, J., Blais, V., Patel, N., Martin, C., Wu, L., Han, G.W., Holleran, B.J., Van der Poorten, O., White, K.L., Hanson, M.A., Sarret, P., Gendron, L., Cherezov, V., Katritch, V., Ballet, S., Liu, Z.-J., Müller, C.E.*, Stevens, R.C.*. (2019). Elucidating the active delta-opioid receptor crystal structure with peptide and small molecule agonists. Science Advances 5 (11), eaax9115. (Article publié).
• Desbiens L , Lapointe C , Gendron L , Gharagozloo M , Vincent L , Pejler G , Gris D , D'Orleans-Juste P. (2019). Experimental autoimmune encephalomyelitis potentiates mouse mast cell protease 4-dependent pressor responses to centrally or systemically administered big endothelin-1. The Journal of pharmacology and experimental therapeutics 370 (3), 437-446. (Article publié).
• Beaudeau JL , Blais V , Holleran BJ , Bergeron A , Piñeyro G , Guérin B , Gendron L , Dory YL. (2019). N-Guanidyl and C-Tetrazole Leu-Enkephalin Derivatives: Efficient Mu and Delta Opioid Receptor Agonists with Improved Pharmacological Properties. ACS chemical neuroscience 10 (3), 1615-1626. (Article publié).
• Gharagozloo M , Mahmoud S , Simard C , Yamamoto K , Bobbala D , Ilangumaran S , Smith MD , Lamontagne A , Jarjoura S , Denault JB , Blais V , Gendron L , Vilariño-Güell C , Sadovnick AD , Ting JP , Calabresi PA , Amrani A , Gris D. (2019). NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS biology 17 (9), e3000451. (Article publié).
• Eiselt E , Gonzalez S , Martin C , Chartier M , Betti C , Longpré JM , Cavelier F , Tourwé D , Gendron L , Ballet S , Sarret P. (2019). Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia. ACS chemical neuroscience 10 (11), 4535-4544. (Article publié).
• *Eiselt E, Côté J, Longpré JM, *Blais V, Sarret P, Gendron L. (2019). The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio. Eur. J. Pharmacol. 848: 80-87. (Article publié).
• *Abdallah K , *Nadeau F , *Bergeron F , *Blouin S , *Blais V , *Bradbury KM , Lavoie CL , Parent JL , Gendron L. (2018). Adeno-associated virus 2/9 delivery of Cre recombinase in mouse primary afferents. Scientific reports 8 (1), 7321. (Article publié).
• Henry MS , Bisht K , Vernoux N , Gendron L , Torres-Berrio A , Drolet G , Tremblay MÈ. (2018). Delta Opioid Receptor Signaling Promotes Resilience to Stress Under the Repeated Social Defeat Paradigm in Mice. Frontiers in molecular neuroscience 11 100. (Article publié).
• *Bella Ndong, D., *Blais, V., *Proteau-Gagné, A., *Holleran, B.J., *Cantin-Savoie, I., *Nadon, J.-F., *Beauchemin, S., Leduc, R., +Guérin, B., +Gendron, L., +Dory, Y.L., +Corresponding authors. (2018). Exploration of the fifth position of Leu-enkephalin and its role in binding and activating the opioid receptors. Peptide Science 111 e24070. (Article publié).
• Charfi I , *Abdallah K , Gendron L , Pineyro G. (2017). Delta opioid receptors recycle to the membrane after sorting to the degradation path. Cellular and molecular life sciences : CMLS tbd tbd. (Article publié).
• Henry MS , Gendron L , Tremblay ME , Drolet G. (2017). Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience. Neural plasticity 2017 1546125. (Article publié).
• *St-Louis É , Degrandmaison J , *Grastilleur S , Génier S , *Blais V , Lavoie C , Parent JL , Gendron L. (2017). Involvement of the coatomer protein complex I in the intracellular traffic of the delta opioid receptor. Molecular and Cellular Neuroscience 76 53-63. (Article publié).
• *Pirisedigh A , *Blais V , Ait-Mohand S , *Abdallah K , *Holleran BJ , Leduc R , +Dory YL , +Gendron L , +Guérin B; +, corresponding authors. (2017). Synthesis and Evaluation of a (64)Cu-Conjugate, a Selective δ-Opioid Receptor Positron Emission Tomography Imaging Agent. Organic letters 19 (8), 2018-2021. (Article publié).
• *Nadon JF, *Rochon K , *Grastilleur S , *Langlois G , *Dao TT , *Blais V , +Guérin B , +Gendron L , +Dory YL; +, corresponding authors. (2017). Synthesis of Gly-ψ[(Z)CF=CH]-Phe, a Fluoroalkene Dipeptide Isostere, and Its Incorporation into a Leu-enkephalin Peptidomimetic. ACS chemical neuroscience 8 (1), 40-49. (Article publié).
• Van der Poorten O , Van Den Hauwe R , Eiselt E , Betti C , Guillemyn K , Chung NN , Hallé F , Bihel F , Schiller PW , Tourwé D , Sarret P , Gendron L , Ballet S. (2017). χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds. ACS medicinal chemistry letters 8 (11), 1177-1182. (Article publié).
• Shi M , Paquette B , Thippayamontri T , Gendron L , Guérin B , Sanche L. (2016). Increased radiosensitivity of colorectal tumors with intra-tumoral injection of low dose of gold nanoparticles. International journal of nanomedicine 11 5323-5333. (Article publié).
• Gendron, L., Cahill, C.M., von Zastrow, M., Schiller, P.W. and Pineyro, G. (2016). Molecular pharmacology of δ-opioid receptors. Pharmacological Reviews 68 (3), 631-700. (Article publié).
• *Maltais, J.-S. Simard, E., Froehlich, U., Denault, J.-B., Gendron, L. and Grandbois, M. (2016). iRAGE as a novel carboxymethylated peptide that prevents advanced glycation end product-induced apoptosis and endoplasmic reticulum stress in vascular smooth muscle cells. Pharmacological Research 104 176-185. (Article publié).
• *Beaudry, H., +Gendron, L. and +Moron-Concepción, J.; +, corresponding authors. (2015). Implication of DOP2 but not DOP1 in development of morphine analgesic tolerance in a rat model of chronic inflammatory pain. Eur J Neurosci 41 (7), 899-905. (Article publié).
• Gendron, L., Mittal, N., *Beaudry, H. and Walwyn, W. (2015). Recent advances on the delta opioid receptor: From trafficking to function. British Journal of Pharmacology 172 (2), 403-419. (Article publié).
• *H Beaudry, *A-A Mercier-Blais, *C Delaygue, C Lavoie, J-L Parent, W Neugebauer and L Gendron. (2015). Regulation of [mu]- and [delta]-Opioid Receptor Functions: Involvement of Cyclin-Dependent Kinase 5. British Journal of Pharmacology 172 (10), 2573-2587. (Article publié).
• Thomas JB, Giddings AM, Wiethe RW, Olepu S, Warner KR, Sarret P, Gendron L, Longpre JM, Zhang Y, Runyon SP, Gilmour BP. (2014). Identification of 1-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane Carboxylic Acid as a Selective Nonpeptide Neurotensin Receptor Type 2 Compound. Journal of Medicinal Chemistry 57 (12), 5318-5332. (Article publié).
• Thomas JB, Giddings AM, Wiethe RW, Olepu S, Warner KR, Sarret P, Gendron L, Longpre JM, Zhang Y, Runyon SP, Gilmour BP. (2014). Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2. J Med Chem 57 (17), 7472-7. (Article publié).
• *Desroches, J., Bouchard, J.-F., +Gendron, L. and +Beaulieu, P.; +, corresponding authors. (2014). Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 261 23-42. (Article publié).
• *Bourassa, P., Grandbois, M. and Gendron, L. (2014). Label-Free Monitoring of Mu Opioid Receptor-Mediated Signaling. Molecular Pharmacology 86 (2), 138-149. (Article publié).
• Cabañero D , Baker A , Zhou S , Hargett GL , Irie T , Xia Y , *Beaudry H , Gendron L , Melyan Z , Carlton SM , Morón JA. (2013). Pain after Discontinuation of Morphine Treatment Is Associated with Synaptic Increase of GluA4-Containing AMPAR in the Dorsal Horn of the Spinal Cord. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 38 (8), 1472-1484. (Article publié).
• *Rochon K , *Proteau-Gagné A , *Bourassa P , *Nadon JF , Côté J , *Bournival V , Gobeil F , Guérin B , Dory YL , Gendron L. (2013). Preparation and Evaluation at the Delta Opioid Receptor of a Series of Linear Leu-Enkephalin Analogues Obtained by Systematic Replacement of the Amides. ACS chemical neuroscience 4 (8), 1204-1216. (Article publié).
• *Normandin, A., Luccarini, P., Molat, J.-L., +Gendron, L. and +Dallel, R.; +, corresponding authors. (2013). Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats. The Journal of neuroscience : the official journal of the Society for Neuroscience 33 (28), 11703-11714. (Article publié).
• *Proteau-Gagné, A., *Rochon, K., *Roy, M., *Albert, P.-J., +Guérin, B., +Gendron, L. and +Dory, Y.L.; +, corresponding authors. (2013). Systematic replacement of amides by 1,4-disubstituted[1,2,3]triazoles in Leu-enkephalin and the impact on the delta opioid receptor activity. Bioorganic & medicinal chemistry letters 23 (19), 5267-5269. (Article publié).
• *Parent AJ , Beaudet N , *Beaudry H , *Bergeron J , Bérubé P , Drolet G , Sarret P , Gendron L. (2012). Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain. Behavioural brain research 229 (1), 160-167. (Article publié).
• *Maltais JS , Denault JB , Gendron L , Grandbois M. (2012). Label-free monitoring of apoptosis by surface plasmon resonance detection of morphological changes. Apoptosis : an international journal on programmed cell death 17 (8), 916-925. (Article publié).
• *Beaudry H , *Dubois D , Gendron L. (2011). Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli. The Journal of neuroscience : the official journal of the Society for Neuroscience 31 (37), 13068-13077. (Article publié).
• *Bournival V , Desjardins R , Campbell S , Roberge C , Doueik A , Gendron L , Payet MD , Gallo-Payet N , Day R , Praud JP. (2011). Presence of task-1 channel in the laryngeal mucosa in the newborn lamb. Experimental lung research 37 (4), 205-211. (Article publié).
• *Otis V , Sarret P , Gendron L. (2011). Spinal activation of delta opioid receptors alleviates cancer-related bone pain. Neuroscience 183 221-229. (Article publié).
• Roussy G , *Beaudry H , Lafrance M , Belleville K , Beaudet N , Wada K , Gendron L , Sarret P. (2010). Altered morphine-induced analgesia in neurotensin type 1 receptor null mice. Neuroscience 170 (4), 1286-1294. (Article publié).
• Doré-Savard L , *Otis V , Belleville K , Lemire M , Archambault M , Tremblay L , Beaudoin JF , Beaudet N , Lecomte R , Lepage M , Gendron L , Sarret P. (2010). Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PloS one 5 (10), e13774. (Article publié).
• *Dubois D , Gendron L. (2010). Delta opioid receptor-mediated analgesia is not altered in preprotachykinin A knockout mice. The European journal of neuroscience 32 (11), 1921-1929. (Article publié).
• *Proteau-Gagné A , *Bournival V , *Rochon K , Dory YL , Gendron L. (2010). Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the ?-Opioid Receptor. ACS chemical neuroscience 1 (11), 757-769. (Article publié).

Chapitres de livre

• Louis Gendron, Karim Nagi, Manel Zeghal, Patrick M. Giguère and Graciela Pineyro. (2019). Molecular aspects of delta opioid receptors. Gerald Litwack. Vitamins and Hormones; OPIOID HORMONES (VH 111, 49-90). Royaume-Uni : Elsevier. (Article accepté).
• Génier S , Degrandmaison J , Lavoie CL , Gendron L , Parent JL. (2019). Monitoring the Aggregation of GPCRs by Fluorescence Microscopy. Tiberi, M.. Methods Mol Biol (1947, 289-302). États-Unis : Humana Press. (Article publié).
• Abdallah K , Gendron L. (2018). The Delta Opioid Receptor in Pain Control. Jutkiewicz E.. Hankbook of Experimental Pharmacology (247, 147-177). Suisse : Springer. (Article publié).
• *Bourassa, P., Söllradl, T., *Maltais, J.-S., Charette, P.G., Gendron, L., Grandbois, M. (2015). Surface Plasmon Resonance to Study Cell Signaling and GPCR Functional Selectivity in Live Cells. Fang, Ye. Label-Free Biosensor Methods in Drug Discovery (53, 183-195). États-Unis : Springer New York. (Article publié).

Articles de conférence

• *Bergeron, F. *Berthiaume, S. *Quirion, B. *St-Louis, É. *Blais, V. Parent, J.-L. Lavoie, C. Gendron, L. (2018). Cdk5-mediated phosphorylation of the delta opioid receptor: a key process for the regulation of cell surface receptors. Society for Neuroscience. (Article publié).
• Eiselt, E. Betti, C. Martin, C. Longpré, J.-M. Spetea, M. Ballet, S. Gendron, L. Sarret, P. (2018). Development of opioid/neurotensin bifunctional hybrid peptides for the treatment of pain. World meeting of the International Association for the Study of Pain. (Article publié).
• Claff, T. *Blais, V. *Holleran, B. Patel, N. Wu, L. Yu, J. Ballet, S. Gendron, L. Katritch, V. Liu, Z.-J. Müller, C. E. Sarret, P. Stevens, R. C. (trainees and staff, then professors are listed in alphabetical order). (2018). Facilitating lipidic cubic phase crystallization experiments with newopioid receptor agonists. Annual Meeting of the German Pharmaceutical Society – DPhG. (Article publié).
• *Grastilleur, S. Degrandmaison, J. *Simard, J. Parent, J.-L. Lavoie, C. Gendron, L. (2018). La régulation constitutive du récepteur aux opioïdes de type Delta (DOP) par les petites protéines G Rab5 et Rab4. Club de recherche clinique du Québec (CRCQ). (Article publié).
• Van Den Hauwe, R. Van der Poorten, O. Ballet, S. *Eiselt, E. Sarret, P. Gendron, L. Tourwé, D. (2018). Synthesis of novel arylazepinone dipeptide mimetics and 1,5-benzothiazepinones as local constraints in peptidomimetic design. 35th European Peptide Symposium. (Article publié).
• *Abdallah, K., Degrandmaison, J., *Blais, V., *Bradbury, K., *Bergeron, F., *Fontes, K., Lavoie, C.L., Cahill, C.M., Boulter, J., Parent, J.L. and Gendron, L. (2017). International Narcotics Research Conference. (Article publié).
• *Abdallah, K., Degrandmaison, J., *Blais, V., *Bradbury, K., *Bergeron, F., *Fontes, K., Lavoie, C.L., Cahill, C.M., Boulter, J., Parent, J.L. and Gendron, L. (2017). A conditional knockin mice to study the delta opioid receptor in pain pathways. Society for Neuroscience. (Article publié).
• *Eiselt, E., *Blais, V., Longpré, J.-M., Sarret, P. and Gendron, L. (2017). Combining neurotensin and opioid receptor agonists to relieve pain. Society for Neuroscience. (Article publié).
• *Grastilleur, S., *Simard, J., *Blais, V., Parent, J.-L., Lavoie, C.L. and Gendron, L. (2017). DOPr displays constitutive internalization and sorting to the rapid recycling pathway. Society for Neuroscience. (Article publié).
• Henry, M.S., Bisht, K., Vernoux, N., Gendron, L., Drolet, G. and Tremblay, M.-E. (2017). Delta opioid signaling promotes resilience to chronic stress in mice under the repeated social defeat paradigm. 11th Annual Canadian Neuroscience Meeting. (Article publié).
• *Bella Ndong, D., Gendron, L. and Dory, Y. (2017). Développement de macrocycles ayant pour cible le récepteur opioïdergique delta (prix pour meilleur présentation). 1ere Journée scientifique Cancer-Inflammation-Douleur. (Article publié).
• *Grastilleur, S., Lavoie, C. and Gendron, L. (2017). L'internalisation constitutive du récepteur opioïdergique delta. 1ere Journée scientifique Cancer-Inflammation-Douleur. (Article publié).
• *Beaudeau, J.-L., *Blais, V., *Holleran, B., Guérin, B., Gendron, L. and Dory, Y. (2017). New strategies for the development of selective and optimized delta opioid receptor agonists inspired from Leu-enkephalin. American Peptide Symposium. (Article publié).
• Chalaye, P., Beaudet, N., Gagnon-Mailhot, M., Damien, J., Tousignant-Laflamme, Y., Léonard, G., Gendron, L. and Marchand, S. (2017). Strategic Approaches to Personalized Diagnosis and Treatment in Chronic Pain: Standardization of Methods Evaluating Conditioned Pain Mechanisms (CPM). Chronic Pain Network Annual Meeting. (Article publié).
• *Beaudeau, J.-L., Gendron, L. and Dory, Y. (2017). Synthesis and evaluation at the delta opioid receptor of analogues of Leu-enkephalin peptidomimetics with improved pharmacokinetics (prix pour meilleure présentation). 1ere Journée scientifique Cancer-Inflammation-Douleur. (Article publié).
• *Eiselt, E., Gendron, L. and Sarret, P. (2017). Use of non-invasive Trojan horse strategy to improve the delivery of opioid pain relief medications to the brain. 1ere Journée scientifique Cancer-Inflammation-Douleur. (Article publié).
• *Grastilleur, S., *Simard, J., Parent, J.-L., Lavoie, C. and Gendron, L. (2016). Constitutive internalization of delta opioid receptors. Society for Neuroscience. (Article publié).
• *Abdallah, K., *Blais, V., *Bradbury, K., *Fontes, K., Parent, J.-L., Cahill, C.M., Boulter, J. and Gendron, L. (2016). Knockin of delta opioid receptors in primary afferents alleviates heat-induced pain. Society for Neuroscience. (Article publié).
• *A. Pirisedigh, Y. L. Dory, L. Gendron and B. Guérin. (2016). Preparation and evaluation of a series of 19F-enkephalin analogues: the first step in the design of potent and selective 18F-labeled PET tracers for delta opioid receptor imaging. 252nd ACS National Meeting. (Article publié).
• *Eiselt, E., *Otis, V., Belleville, K., Larocque, A., Régina, A., Longpré, J.-M., Demeule, M., Sarret, P. and Gendron, L. (2016). Use of a non-invasive Trojan horse strategy to improve the delivery of opioid pain relief medications to the brain. Society for Neuroscience meeting. (Article publié).
• Iness Charfi, *Khaled Abdallah, Louis Gendron, Graciela Pineyro. (2015). Delta opioid receptor recycles from late endosomal compartments. GPCR Retreat. (Article publié).
• Iness Charfi, *Khaled Abdallah, Louis Gendron, Graciela Pineyro. (2015). Delta opioid receptor recycles from late endosomal compartments. Society for Neuroscience 2015. (Article publié).
• *Azadeh Pirisedigh, Yves Dory, Louis Gendron, Brigitte Guérin. (2015). Design, Synthesis and Evaluation of Selective 19F-Enkephalin Analogs; A First Step in the Development of PET Tracers for DOP Imaging. Québec and Ontario Mini-Symposium in Synthetic and Bioorganic Chemistry. (Article publié).
• *Sébastien Grastilleur, Jean-Luc Parent, Christine Lavoie, Louis Gendron. (2015). Identification and characterization of interacting partners involved in the trafficking of the delta opioid receptor. GPCR Retreat. (Article publié).
• L. GENDRON, E. ST-LOUIS, J.-L. PARENT. (2015). Implication of COPB1 in intracellular retention of the delta opioid receptor. Society for Neuroscience 2015. (Article publié).
• *Etienne St-Louis, Jean-Luc Parent, Louis Gendron. (2015). Implication of COPB1 in intracellular retention of the delta opioid receptor. International Narcotics Research Conference. (Article publié).

Autres contributions

Cours enseignés

• Writing and Publishing a Scientific Paper. EFD954. (2017-01-11).Université de Sherbrooke. Canada.
• Systems Physiology. (2013-01-08).Université de Sherbrooke. Canada.
• Peptide Pharmacology. PHAR703B. (2011-01-04 à 2011-12-17).McGill University. Canada.
• Molecular and cellular endocrinology. PHS 712. (2010-01-06 à 2014-12-20).Université de Sherbrooke. Canada.
• Principles of Pharmacology. (2010-01-05 à 2013-12-14).Université de Sherbrooke. Canada.
• Scientific interaction. PHR 712. (2009-01-06 à 2009-12-19).Université de Sherbrooke. Canada.
• Abus et dépendance. PHR 510. (2008-01-08).Université de Sherbrooke. Canada.
• Pharmacology of the nervous system. PHR500. (2008-01-08).Université de Sherbrooke. Canada.
• Chemical mediators of neurotransmission. PHR 703. (2008-01-07 à 2012-12-22).Université de Sherbrooke. Canada.
• Neurophysiology of pain. GDL 720. (2008-01-07).Université de Sherbrooke. Canada.

Gestion d'évènements

• Co-chair and Treasurer. (2019) 20th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec. (Conférence).

Présentations

• (2019). Le cannabis thérapeutique: Entre mythes et réalité. Congrès de la Fédération des kinésiologues du Québec (May 3rd). Orford, Canada
• (2019). Le cannabis thérapeutique: Entre mythes et réalité. Association de la fibromyalgie de l'Estrie (May 4th). Sherbrooke, Canada
• (2018). Identification of Rab10 as a regulator of the delta-opioid receptor trafficking using an epitope tagged knockin mouse. 19th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec (Oct 26th). Detroit, États-Unis
• (2018). Le cannabis : drogue ou médicament. Le cannabis et moi (Regroupement des étudiants chercheurs de l'Université de Sherbrooke). Sherbrooke, Canada
• (2018). Le cannabis : drogue ou médicament. PAINtalks 2018 (Oct 5th). Quebec, Canada
• (2017). Investigating delta opioid receptors in a new conditional knockin mouse. International Narcotics Research Conference. Chicago, États-Unis
• (2017). Targeting the Delta Opioid Receptor to Alleviate Pain. Hotchkiss Brain Institute, University of Calgary. Calgary, Canada
• (2017). Traiter la douleur, un défi de taille. 1ere Journée scientifique en Cancer-Inflammation-Douleur. Orford, Canada
• (2016). Molecular mechanisms controlling the delta opioid receptor trafficking. Department of Physiology, McGill University. Montreal, Canada
• (2016). Rôle de la boucle i2 dans la régulation du récepteur opioïde delta. Université d’Auvergne. Clermont-Ferrand, France
• (2016). Rôle de la voie de sécrétion régulée dans le contrôle des fonctions analgésiques du récepteur opioïde delta. Congrès de la Société de Neuroendocrinologie (SNE). Corte, France
• (2016). The delta opioid receptor as a target to reduce morphine tolerance. 37th Annual Scientific Meeting of the Canadian Pain Society. Vancouver, Canada
• (2015). Awakening the delta opioid receptor for the treatment of pain. Department of Pharmacology The University of Texas Health Science Center at San Antonio. San Antonio, États-Unis
• (2014). A "DOR" for new analgesics. Frontiers in pain research lecture series/The Alan Edwards Centre for Research on Pain/McGill University. Montreal, Canada
• (2013). Regulating the delta opioid receptor for pain control. University of Michigan. Ann Arbor, États-Unis
• (2013). Role and regulation of the delta opioid receptor. International Narcotics Research Conference. Cairns, Australie
• (2012). The delta opioid receptors : Where are they and what are they doing?. Washington University, Department of Anesthesiology, St-Louis, USA. St-Louis, États-Unis